To cleave or not to cleave: therapeutic gene editing with and without programmable nucleases

Nat Rev Drug Discov. 2017 Apr;16(4):296. doi: 10.1038/nrd.2017.42. Epub 2017 Mar 17.

Authors

Tod M Woolf¹, Channabasavaiah B Gurumurthy², Frederick Boyce³, Eric B Kmiec⁴

Affiliations

¹ ETAGEN Pharma, Inc., Cambridge, Massachusetts 01239, USA.
² Mouse Engineering Core Facility, University of Nebraska Medical Center, Omaha, Nebraska 68198, USA.
³ Massachusetts General Hospital, Cambridge, Massachusetts 02139, USA.
⁴ Gene Editing Institute for Translational Cancer Research, Helen F. Graham Cancer Center, and Research Institute, Newark, Delaware 19713, USA.

PMID: 28303022
DOI: 10.1038/nrd.2017.42

No abstract available

MeSH terms

Animals
Clinical Trials as Topic / methods*
Deoxyribonucleases / genetics*
Gene Editing / methods*
Genetic Engineering / methods
Humans

Substances

Deoxyribonucleases